Tissue expression of gelsolin in oral carcinogenesis progression and its clinicopathological implications

Oral Oncology

Volumn 42, Issue 6, 2006, Pages 599-606

  Shieh, Dar Bin ^a   Chen, I Wen ^a   Wei, Tsai Yin ^b   Shao, Chuin Yi ^a   Chang, Hsin Ju ^c   Chung, Ching Hung ^a   Wong, Tung Yiu ^a   Jin, Ying Tai ^a  

^a NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^b MACKAY MEMORIAL HOSPITAL   (Taiwan)

^c KAOHSIUNG VETERANS GENERAL HOSPITAL   (Taiwan)

Author keywords

Gelsolin; Invasion; Oral squamous cell carcinoma; Prognosis

Indexed keywords

GELSOLIN;

ADULT; ARTICLE; CANCER INVASION; CARCINOGENESIS; CELL FUNCTION; CELL GROWTH; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; METASTASIS; MOUTH CANCER; MOUTH MUCOSA; OUTCOME ASSESSMENT; PATHOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SQUAMOUS CELL CARCINOMA; STAINING; TUMOR VOLUME;

AGE FACTORS; CARCINOMA, SQUAMOUS CELL; DISEASE PROGRESSION; FEMALE; GELSOLIN; HUMANS; KERATINOCYTES; MALE; MIDDLE AGED; MOUTH MUCOSA; MOUTH NEOPLASMS; NEOPLASM PROTEINS; PRECANCEROUS CONDITIONS; PROGNOSIS;

EID: 33745329568     PISSN: 13688375     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.oraloncology.2005.10.021     Document Type: Article

References (40)

1. Carvalho A.L., Nishimoto I.N., Califano J.A., and Kowalski L.P. Trends in incidence and prognosis for head and neck cancer in the United States: a site-specific analysis of the SEER database. Int J Cancer 114 (2005) 806-816
2. Chen C.J., You S.L., Lin L.H., Hsu W.L., and Yang Y.W. Cancer epidemiology and control in Taiwan: a brief review. Jpn J Clin Oncol 32 suppl (2002) S66-S81
3. Button E., Shapland C., and Lawson D. Actin, its associated proteins and metastasis. Cell Motil Cytoskel 30 (1995) 247-251
4. Pawlak G., and Helfman D.M. Cytoskeletal changes in cell transformation and tumorigenesis. Curr Opin Genet Dev 11 (2001) 41-47
5. Azuma T., Witke W., Stossel T.P., Hartwig J.H., and Kwiatkowski D.J. Gelsolin is a downstream effector of rac for fibroblast motility. Embo J 17 (1998) 1362-1370
6. Cunningham C.C., Stossel T.P., and Kwiatkowski D.J. Enhanced motility in NIH 3T3 fibroblasts that overexpress gelsolin. Science 251 (1991) 1233-1236
7. De Corte V., Bruyneel E., Boucherie C., Mareel M., Vandekerckhove J., and Gettemans J. Gelsolin-induced epithelial cell invasion is dependent on Ras-Rac signaling. Embo J 21 (2002) 6781-6790
8. Kothakota S., Azuma T., Reinhard C., et al. Caspase-3-generated fragment of gelsolin: effector of morphological change in apoptosis. Science 278 (1997) 294-298
9. Kwiatkowski D.J. Functions of gelsolin: motility, signaling, apoptosis, cancer. Curr Opin Cell Biol 11 (1999) 103-108
10. Kuzumaki N., Tanaka M., Sakai N., and Fujita H. Tumor suppressive function of gelsolin. Gan to Kagaku Ryoho [Jpn J Cancer Chemotherapy] 24 (1997) 1436-1441
11. Geng Y.J., Azuma T., Tang J.X., Hartwig J.H., Muszynski M., Wu Q., et al. Caspase-3-induced gelsolin fragmentation contributes to actin cytoskeletal collapse, nucleolysis, and apoptosis of vascular smooth muscle cells exposed to proinflammatory cytokines. Eur J Cell Biol 77 (1998) 294-302
12. Vandekerckhove J., Bauw G., Vancompernolle K., Honore B., and Celis J. Comparative two-dimensional gel analysis and microsequencing identifies gelsolin as one of the most prominent downregulated markers of transformed human fibroblast and epithelial cells. J Cell Biol 111 (1990) 95-102
13. Mullauer L., Fujita H., Ishizaki A., and Kuzumaki N. Tumor-suppressive function of mutated gelsolin in ras-transformed cells. Oncogene 8 (1993) 2531-2536
14. Tanaka M., Mullauer L., Ogiso Y., Fujita H., Moriya S., Furuuchi K., et al. Gelsolin: a candidate for suppressor of human bladder cancer. Cancer Res 55 (1995) 3228-3232
15. Dosaka-Akita H., Hommura F., Fujita H., Kinoshita I., Nishi M., Morikawa T., et al. Frequent loss of gelsolin expression in non-small cell lung cancers of heavy smokers. Cancer Res 58 (1998) 322-327
16. Shieh D.B., Godleski J., Herndon II J.E., Azuma T., Mercer H., Sugarbaker D.J., et al. Cell motility as a prognostic factor in Stage I nonsmall cell lung carcinoma: the role of gelsolin expression. Cancer 85 (1999) 47-57
17. Asch H.L., Head K., Dong Y., Natoli F., Winston J.S., Connolly J.L., et al. Widespread loss of gelsolin in breast cancers of humans, mice, and rats. Cancer Res 56 (1996) 4841-4845
18. Lee H.K., Driscoll D., Asch H., Asch B., and Zhang P.J. Downregulated gelsolin expression in hyperplastic and neoplastic lesions of the prostate. Prostate 40 (1999) 14-19
19. Kuzumaki N. Progress of research on tumor suppressor genes. Hokkaido Igaku Zasshi 71 (1996) 133-137
20. Thor A.D., Edgerton S.M., Liu S., Moore II D.H., and Kwiatkowski D.J. Gelsolin as a negative prognostic factor and effector of motility in erbB-2-positive epidermal growth factor receptor-positive breast cancers. Clin Cancer Res 7 (2001) 2415-2424
21. Rao J., Seligson D., Visapaa H., Horvath S., Eeva M., Michel K., et al. Tissue microarray analysis of cytoskeletal actin-associated biomarkers gelsolin and E-cadherin in urothelial carcinoma. Cancer 95 (2002) 1247-1257
22. Kim M.S., Li S.L., Bertolami C.N., Cherrick H.M., and Park N.H. State of p53, Rb and DCC tumor suppressor genes in human oral cancer cell lines. Anticancer Res 13 (1993) 1405-1413
23. Matsui T., Ota T., Ueda Y., Tanino M., and Odashima S. Isolation of a highly metastatic cell line to lymph node in human oral squamous cell carcinoma by orthotopic implantation in nude mice. Oral Oncol 34 (1998) 253-256
24. Chaponnier C., and Gabbiani G. Gelsolin modulation in epithelial and stromal cells of mammary carcinoma. Am J Pathol 134 (1989) 597-603
25. Furuuchi K., Fujita H., Tanaka M., et al. Gelsolin as a suppressor of malignant phenotype in human colon cancer. Tumor Target 2 (1997) 277-283
26. Zhang L., Zhou W., and Velculescu V.E. Gene expression profiles in normal and cancer cells. Science 276 (1997) 1268-1272
27. Asch H.L., Winston J.S., Edge S.B., Stomper P.C., and Asch B.B. Down-regulation of gelsolin expression in human breast ductal carcinoma in situ with and without invasion. Breast Cancer Res Treat 55 (1999) 179-188
28. Sagawa N., Fujita H., Banno Y., Nozawa Y., Katoh H., and Kuzumaki N. Gelsolin suppresses tumorigenicity through inhibiting PKC activation in a human lung cancer cell line, PC10. Br J Cancer 88 (2003) 606-612
29. Kamitani H., Taniura S., Watanabe K., Sakamoto M., Watanabe T., and Eling T. Histone acetylation may suppress human glioma cell proliferation when p21 WAF/Cip1 and gelsolin are induced. J Neurooncol 4 (2002) 95-101
30. Sazawa A., Watanabe T., Tanaka M., et al. Adenovirus mediated gelsolin gene therapy for orthotopic human bladder cancer in nude mice. J Urol 168 (2002) 1182-1187
31. Hockel M., and Vaupel P. Biological consequences of tumor hypoxia. Semin Oncol 28 (2001) 36-41
32. Scandurro A.B., Weldon C.W., Figueroa Y.G., Alam J., and Beckman B.S. Gene microarray analysis reveals a novel hypoxia signal transduction pathway in human hepatocellular carcinoma cells. Int J Oncol 19 (2001) 129-135
33. Niizeki H., Kobayashi M., Horiuchi I., et al. Hypoxia enhances the expression of autocrine motility factor and the motility of human pancreatic cancer cells. Br J Cancer 86 (2002) 1914-1919
34. Endres M., Fink K., Zhu J., et al. Neuroprotective effects of gelsolin during murine stroke. J Clin Invest 103 (1999) 347-354
35. Fujita H., Laham L.E., Janmey P.A., et al. Functions of [His321] gelsolin isolated from a flat revertant of ras-transformed cells. Eur J Biochem 229 (1995) 615-620
36. Sakai N., Ohtsu M., Fujita H., Koike T., and Kuzumaki N. Enhancement of G2 checkpoint function by gelsolin transfection in human cancer cells. Exp Cell Res 251 (1999) 224-233
37. Karliner J.S., Honbo N., Summers K., Gray M.O., and Goetzl E.J. The lysophospholipids sphingosine-1-phosphate and lysophosphatidic acid enhance survival during hypoxia in neonatal rat cardiac myocytes. J Mol Cell Cardiol 33 (2001) 1713-1717
38. Xiong Q., Valero V., Kau V., et al. Female patients with breast carcinoma age 30 years and younger have a poor prognosis: the M.D. Anderson Cancer Center experience. Cancer 92 (2001) 2523-2528
39. Yokota T., Takahashi N., Teshima S., et al. Early gastric cancer in the young: clinicopathological study. Aust NZ J Surg 69 (1999) 443-446
40. Liang J.T., Huang K.C., Cheng A.L., Jeng Y.M., Wu M.S., and Wang S.M. Clinicopathological and molecular biological features of colorectal cancer in patients less than 40 years of age. Br J Surg 90 (2003) 205-214